$CBIO insider trading
Over the last 12 months, Crescent Biopharma insiders reported 2 buys totaling $30.6M and 7 sales totaling $1.2M across SEC Form 4 filings. 78% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $30.6M 2 events
- Sold · 12m
- $1.2M 7 events
- Events · 12m
- 9 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 78% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Fairmount Funds Management LLCD·10% | ▲ Buy | 853,450 | $14.5 | $12.4M | +31.1% | indirect |
| Jun 22, 2026 | Lynch RyanSee Remarks · O | ▼ Sale | 465 | $17.99 | $8K | -3.2% | plan |
| Jun 22, 2026 | Pinkas JanChief Scientific Officer · O | ▼ Sale | 1,288 | $17.99 | $23K | -5.5% | plan |
| Jun 22, 2026 | Scalzo Richard WilliamChief Financial Officer · O | ▼ Sale | 1,112 | $17.99 | $20K | -5.2% | plan |
| Jun 22, 2026 | Bispham Barbara HarlinSee Remarks · O | ▼ Sale | 1,218 | $17.99 | $22K | -5.9% | plan |
| Jun 22, 2026 | Im Ellie EunkyungChief Medical Officer · O | ▼ Sale | 1,219 | $17.99 | $22K | -5.2% | plan |
| Jun 22, 2026 | McNeill JonathanPresident and COO · O | ▼ Sale | 20,549 | $17.99 | $370K | -12.9% | plan |
| Jun 22, 2026 | Brumm Joshua TChief Executive Officer · O·D | ▼ Sale | 42,305 | $17.99 | $761K | -13.1% | plan |
| Dec 4, 2025 | Fairmount Funds Management LLCD·10% | ▲ Buy | 1,360,000 | $13.41 | $18.2M | +98% | indirect |
Every $CBIO filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Crescent Biopharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CBIO feed.